OK-432硬化疗法治疗头颈部淋巴管瘤：长期随访结果
OK-432 sclerotherapy in head and neck lymphangiomas: long-term follow-up result.
作者信息
Yoo Jae Chul, Ahn Youngjin, Lim Yune Syung, Hah J Hun, Kwon Tack-Kyun, Sung Myung-Whun, Kim Kwang Hyun
机构信息
Department of Otorhinolaryngology, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Otolaryngol Head Neck Surg. 2009 Jan;140(1):120-3. doi: 10.1016/j.otohns.2008.10.026.
INTRODUCTION
Nonsurgical treatments, such as sclerotherapy have been attempted for head and neck lymphagiomas. Of the available sclerosing agents, picibanil has shown satisfactory short-term treatment results in many studies, but no study has presented long-term treatment results. Accordingly, in the present study, the authors retrospectively reviewed the long-term treatment results of picibanil sclerotherapy.
MATERIALS AND METHODS
Fifty-five lymphangioma patients who underwent picibanil sclerotherapy were enrolled. Data about initial and long-term response, recurrence, and excision rate were collected.
RESULTS
Initial response rates were 83.5 percent and long-term response rates were 76.3 percent.
CONCLUSION
Initial and the long-term response rate were equally good for lymphangioma.
引言
已经尝试对头颈部淋巴管瘤进行非手术治疗，如硬化疗法。在现有的硬化剂中，多西环素在许多研究中显示出令人满意的短期治疗效果，但尚无研究呈现长期治疗效果。因此，在本研究中，作者回顾性地分析了多西环素硬化疗法的长期治疗效果。
材料与方法
纳入55例行多西环素硬化疗法的淋巴管瘤患者。收集有关初始和长期反应、复发及切除率的数据。
结果
初始反应率为83.5%，长期反应率为76.3%。
结论
淋巴管瘤的初始和长期反应率同样良好。
Zotero 插件